

Anti-PDCD1/PD-1/CD279 Antibody (Budigalimab)

Introduction

Budigalimab (ABBV 181; PR 1648817) is a humanIgG1 Monoclonal antibody targeting programmed cell death 1 (PD-1) receptors. Budigalimab has an Fc mutation that reduces Fc receptor interactions and inhibition of effector factors.

Product parameters

Alternative Names	ABBV-181, PR-1648817
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	2098225-93-3
Molecular Weight	144.76 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com